{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:36:51Z","timestamp":1787027811466,"version":"build-2736575974"},"reference-count":151,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Iron metabolism plays a dual role in cancer, serving as an essential nutrient for cellular functions and a potential catalyst for tumor growth and immune evasion. Here, we cover the complex interplay between iron levels within the serum or in the microenvironment and cancer therapy, focusing on how iron deficiency and overload can impact immune function, tumor progression, and treatment efficacy. On the one hand, we highlight iron deficiency as a factor of primary immune responses and its adverse effects on anti-cancer immunotherapy efficacy. On the other hand, we also stress the impact of iron overload as an essential factor contributing to tumor growth, creating a suppressive tumor microenvironment that hinders immune checkpoint inhibitor immunotherapy. Overall, we emphasize the necessity of the personalized management of iron levels in oncology patients as a critical element in treatment optimization to achieve favorable outcomes. Based on these considerations, we believe that close and careful monitoring and the tailored balancing of iron supplementation strategies should be the subject of further clinical studies, and routine iron management should be implemented in oncology clinical practice and integrated into cancer therapy protocols.<\/jats:p>","DOI":"10.3390\/cancers16244156","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T03:51:08Z","timestamp":1734061868000},"page":"4156","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The Impact of Iron on Cancer-Related Immune Functions in Oncology: Molecular Mechanisms and Clinical Evidence"],"prefix":"10.3390","volume":"16","author":[{"given":"Omar","family":"Badran","sequence":"first","affiliation":[{"name":"Department of Oncology, Emek Medical Center, Afula 1834111, Israel"},{"name":"Technion Integrated Cancer Center, Faculty of Medicine, Technion, Haifa 3525422, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6933-9385","authenticated-orcid":false,"given":"Idan","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Emek Medical Center, Afula 1834111, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Bar-Sela","sequence":"additional","affiliation":[{"name":"Department of Oncology, Emek Medical Center, Afula 1834111, Israel"},{"name":"Technion Integrated Cancer Center, Faculty of Medicine, Technion, Haifa 3525422, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.tips.2021.05.001","article-title":"Iron metabolism: Pathophysiology and pharmacology","volume":"42","author":"Roemhild","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-nutr-062320-112625","article-title":"Molecular Mechanisms of Iron and Heme Metabolism","volume":"42","author":"Dutt","year":"2022","journal-title":"Annu. Rev. Nutr."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Carter, A., Racey, S., and Veuger, S. (2022). The Role of Iron in DNA and Genomic Instability in Cancer, a Target for Iron Chelators That Can Induce ROS. Appl. Sci., 12.","DOI":"10.3390\/app121910161"},{"key":"ref_4","first-page":"1143","article-title":"Iron metabolism and its contribution to cancer (Review)","volume":"54","author":"Chen","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Guo, Q., Li, L., Hou, S., Yuan, Z., Li, C., Zhang, W., Zheng, L., and Li, X. (2021). The Role of Iron in Cancer Progression. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.778492"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"43ra56","DOI":"10.1126\/scitranslmed.3001127","article-title":"Ferroportin and iron regulation in breast cancer progression and prognosis","volume":"2","author":"Pinnix","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_7","first-page":"541","article-title":"Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer","volume":"21","author":"Yang","year":"2001","journal-title":"Anticancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF00265663","article-title":"Transferrin receptor expression by human bladder transitional cell carcinomas","volume":"15","author":"Seymour","year":"1987","journal-title":"Urol. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1158\/0008-5472.CAN-13-1224","article-title":"IRP2 regulates breast tumor growth","volume":"74","author":"Wang","year":"2014","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3324\/haematol.2014.112813","article-title":"The role of inflammation, iron, and nutritional status in cancer-related anemia: Results of a large, prospective, observational study","volume":"100","author":"Madeddu","year":"2015","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1631\/jzus.B2200194","article-title":"Iron metabolism, ferroptosis, and lncRNA in cancer: Knowns and unknowns","volume":"23","author":"Qu","year":"2022","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.bjhh.2016.05.009","article-title":"Iron deficiency in cancer patients","volume":"38","author":"Naoum","year":"2016","journal-title":"Rev. Bras. De Hematol. E Hemoter."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Busti, F., Marchi, G., Ugolini, S., Castagna, A., and Girelli, D. (2018). Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy. Pharmaceuticals, 11.","DOI":"10.3390\/ph11040094"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/oncolo\/oyac005","article-title":"Impact of Iron-Deficiency Management on Quality of Life in Patients with Cancer: A Prospective Cohort Study (CAMARA Study)","volume":"27","author":"Gluszak","year":"2022","journal-title":"Oncologist"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1016\/j.amjmed.2003.12.008","article-title":"Prevalence and outcomes of anemia in cancer: A systematic review of the literature","volume":"116","author":"Knight","year":"2004","journal-title":"Am. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Brown, R.A.M., Richardson, K.L., Kabir, T.D., Trinder, D., Ganss, R., and Leedman, P.J. (2020). Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00476"},{"key":"ref_17","unstructured":"McDowell, L.A., Kudaravalli, P., Chen, R.J., and Sticco, K.L. (2024). Iron Overload. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1349-7006.2008.01001.x","article-title":"Role of iron in carcinogenesis: Cancer as a ferrotoxic disease","volume":"100","author":"Toyokuni","year":"2009","journal-title":"Cancer Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(13)70174-8","article-title":"Effects of iron overload on chronic metabolic diseases","volume":"2","author":"Manco","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.12659\/MSM.896494","article-title":"The Role of Iron and Iron Overload in Chronic Liver Disease","volume":"22","author":"Milic","year":"2016","journal-title":"Med. Sci. Monit."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S1470-2045(08)70279-1","article-title":"Part I: Liver function in oncology: Biochemistry and beyond","volume":"9","author":"Field","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10238-022-00887-0","article-title":"The new progress in cancer immunotherapy","volume":"23","author":"Shimu","year":"2022","journal-title":"Clin. Exp. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00005-010-0095-9","article-title":"Iron and immunity: Immunological consequences of iron deficiency and overload","volume":"58","author":"Cherayil","year":"2010","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Tymoszuk, P., Nairz, M., Brigo, N., Petzer, V., Heeke, S., Kircher, B., Hermann-Kleiter, N., Klepsch, V., Theurl, I., and Weiss, G. (2020). Iron Supplementation Interferes With Immune Therapy of Murine Mammary Carcinoma by Inhibiting Anti-Tumor T Cell Function. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.584477"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e2318420121","DOI":"10.1073\/pnas.2318420121","article-title":"Iron regulates the quiescence of naive CD4 T cells by controlling mitochondria and cellular metabolism","volume":"121","author":"Kumar","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Barton, J.C., Wiener, H.W., Acton, R.T., and Go, R.C. (2005). TTotal blood lymphocyte counts in hemochromatosis probands with HFE C282Y homozygosity: Relationship to severity of iron overload and HLA-A and -B alleles and haplotypes. BMC Blood Disord., 5.","DOI":"10.1186\/1471-2326-5-5"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s44313-024-00030-w","article-title":"Functional iron deficiency anemia in patients with cancer","volume":"59","author":"Koh","year":"2024","journal-title":"Blood Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1093\/annonc\/mdt118","article-title":"Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia","volume":"24","author":"Ludwig","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e000759","DOI":"10.1136\/bmjgast-2021-000759","article-title":"Iron deficiency anaemia: Pathophysiology, assessment, practical management","volume":"9","author":"Kumar","year":"2022","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00520-016-3511-9","article-title":"Estimating prevalence of functional iron deficiency anaemia in advanced cancer","volume":"25","author":"Neoh","year":"2017","journal-title":"Support Care Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.hoc.2014.04.005","article-title":"Anemia of inflammation","volume":"28","author":"Nemeth","year":"2014","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Bozzini, C., Busti, F., Marchi, G., Vianello, A., Cerchione, C., Martinelli, G., and Girelli, D. (2024). Anemia in patients receiving anticancer treatments: Focus on novel therapeutic approaches. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1380358"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Natalucci, V., Virgili, E., Calcagnoli, F., Valli, G., Agostini, D., Zeppa, S.D., Barbieri, E., and Emili, R. (2021). Cancer Related Anemia: An Integrated Multitarget Approach and Lifestyle Interventions. Nutrients, 13.","DOI":"10.3390\/nu13020482"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Pagani, A., Nai, A., Silvestri, L., and Camaschella, C. (2019). Hepcidin and Anemia: A Tight Relationship. Front. Physiol., 10.","DOI":"10.3389\/fphys.2019.01294"},{"key":"ref_35","first-page":"51","article-title":"The Regulation of Iron Absorption and Homeostasis","volume":"37","author":"Wallace","year":"2016","journal-title":"Clin. Biochem. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/gut.46.2.270","article-title":"Localisation of divalent metal transporter 1 (DMT1) to the microvillus membrane of rat duodenal enterocytes in iron deficiency, but to hepatocytes in iron overload","volume":"46","author":"Trinder","year":"2000","journal-title":"Gut"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000362888","article-title":"Physiology of iron metabolism","volume":"41","author":"Waeber","year":"2014","journal-title":"Transfus. Med. Hemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.bbamcr.2012.03.004","article-title":"Ferroportin-mediated iron transport: Expression and regulation","volume":"1823","author":"Ward","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep4.1717","article-title":"Hepcidin Signaling in Health and Disease: Ironing Out the Details","volume":"5","author":"Kowdley","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/bs.vh.2019.01.002","article-title":"Hepcidin-ferroportin axis in health and disease","volume":"110","author":"Ginzburg","year":"2019","journal-title":"Vitam. Horm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1002\/cam4.4761","article-title":"Iron imbalance in cancer: Intersection of deficiency and overload","volume":"11","author":"Basak","year":"2022","journal-title":"Cancer Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/carcin\/bgp127","article-title":"Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability","volume":"30","author":"Colotta","year":"2009","journal-title":"Carcinogenesis"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"ltad011","DOI":"10.1093\/immadv\/ltad011","article-title":"Blockade of innate inflammatory cytokines TNF\u03b1, IL-1\u03b2, or IL-6 overcomes virotherapy-induced cancer equilibrium to promote tumor regression","volume":"3","author":"Walsh","year":"2023","journal-title":"Immunother. Adv."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Tanaka, T., Narazaki, M., and Kishimoto, T. (2014). IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol., 6.","DOI":"10.1101\/cshperspect.a016295"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","article-title":"The two faces of IL-6 in the tumor microenvironment","volume":"26","author":"Fisher","year":"2014","journal-title":"Semin. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI200420945","article-title":"IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin","volume":"113","author":"Nemeth","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3041738","DOI":"10.1155\/2020\/3041738","article-title":"Effect of Interleukin and Hepcidin in Anemia of Chronic Diseases","volume":"2020","author":"Yacoub","year":"2020","journal-title":"Anemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.mcna.2016.09.005","article-title":"Anemia of Inflammation: A Review","volume":"101","author":"Fraenkel","year":"2017","journal-title":"Med. Clin. N. Am."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Xu, T., Fan, J., Levy, L.B., Zhuang, Y., Bone, C., Huo, J., Gomez, D.R., Liao, Z., and Hu, Y. (2016). Predictive Value of Serum Hepcidin for Disease Outcome in Non-Small Cell Lung Cancer Patients Received Definitive Radio(chemo)therapy. Int. J. Radiat. Oncol. Biol. Phys., 96.","DOI":"10.1016\/j.ijrobp.2016.06.1817"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"di Grazia, A., di Fusco, D., Franz\u00e8, E., Colella, M., Strimpakos, G., Salvatori, S., Formica, V., Laudisi, F., Maresca, C., and Colantoni, A. (2022). Hepcidin Upregulation in Colorectal Cancer Associates with Accumulation of Regulatory Macrophages and Epithelial\u2013Mesenchymal Transition and Correlates with Progression of the Disease. Cancers, 14.","DOI":"10.3390\/cancers14215294"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/1759-7714.12046","article-title":"Increased hepcidin expression in non-small cell lung cancer tissue and serum is associated with clinical stage","volume":"5","author":"Chen","year":"2014","journal-title":"Thorac. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-017-0427-x","article-title":"A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia","volume":"10","author":"Abonour","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Lin, F., Tuffour, A., Hao, G., Peprah, F.A., Huang, A., Zhou, Y., and Zhang, H. (2023). Distinctive modulation of hepcidin in cancer and its therapeutic relevance. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1141603"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.medj.2020.10.004","article-title":"Hepcidin-Mediated Hypoferremia Disrupts Immune Responses to Vaccination and Infection","volume":"2","author":"Frost","year":"2021","journal-title":"Med"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"101227","DOI":"10.1016\/j.blre.2024.101227","article-title":"Absolute and functional iron deficiency: Biomarkers, impact on immune system, and therapy","volume":"68","author":"Leal","year":"2024","journal-title":"Blood Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.cpt.2022.12.002","article-title":"Role of T cells in cancer immunotherapy: Opportunities and challenges","volume":"1","author":"Ahmed","year":"2023","journal-title":"Cancer Pathog. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Ni, S., Yuan, Y., Kuang, Y., and Li, X. (2022). Iron Metabolism and Immune Regulation. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.816282"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Pfeifhofer-Obermair, C., Tymoszuk, P., Nairz, M., Schroll, A., Klais, G., Demetz, E., Engl, S., Brigo, N., and Weiss, G. (2021). Regulation of Th1 T Cell Differentiation by Iron via Upregulation of T Cell Immunoglobulin and Mucin Containing Protein-3 (TIM-3). Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.637809"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Duan, G., Li, J., Duan, Y., Zheng, C., Guo, Q., Li, F., Zheng, J., Yu, J., Zhang, P., and Wan, M. (2022). Mitochondrial Iron Metabolism: The Crucial Actors in Diseases. Molecules, 28.","DOI":"10.3390\/molecules28010029"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e152345","DOI":"10.1172\/JCI152345","article-title":"Iron-dependent epigenetic modulation promotes pathogenic T cell differentiation in lupus","volume":"132","author":"Gao","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"20827","DOI":"10.1074\/jbc.M116.727701","article-title":"Iron Deprivation Induces Transcriptional Regulation of Mitochondrial Biogenesis","volume":"291","author":"Rensvold","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","article-title":"Differentiation of Effector CD4 T Cell Populations","volume":"28","author":"Zhu","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1038\/s41467-019-11002-5","article-title":"Iron-dependent histone 3 lysine 9 demethylation controls B cell proliferation and humoral immune responses","volume":"10","author":"Jiang","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Bailey, S.R., Nelson, M.H., Himes, R.A., Li, Z., Mehrotra, S., and Paulos, C.M. (2014). Th17 Cells in Cancer: The Ultimate Identity Crisis. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00276"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Ramesh, P., Shivde, R., Jaishankar, D., Saleiro, D., and le Poole, I.C. (2021). A Palette of Cytokines to Measure Anti-Tumor Efficacy of T Cell-Based Therapeutics. Cancers, 13.","DOI":"10.3390\/cancers13040821"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3892\/ol.2022.13355","article-title":"Interferon \u03b1 and its effects on cancer cell apoptosis (Review)","volume":"24","author":"Shi","year":"2022","journal-title":"Oncol. Lett."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Mertens, C., Marques, O., Horvat, N.K., Simonetti, M., Muckenthaler, M.U., and Jung, M. (2021). The Macrophage Iron Signature in Health and Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168457"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.imbio.2017.11.001","article-title":"Macrophages: Their role, activation and polarization in pulmonary diseases","volume":"223","author":"Arora","year":"2018","journal-title":"Immunobiology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1159\/000336423","article-title":"Macrophages and systemic iron homeostasis","volume":"4","author":"Ganz","year":"2012","journal-title":"J. Innate Immun."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Boutilier, A.J., and Elsawa, S.F. (2021). Macrophage Polarization States in the Tumor Microenvironment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22136995"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/eji.200939889","article-title":"Differential regulation of iron homeostasis during human macrophage polarized activation","volume":"40","author":"Recalcati","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.3324\/haematol.2010.023879","article-title":"Polarization dictates iron handling by inflammatory and alternatively activated macrophages","volume":"95","author":"Corna","year":"2010","journal-title":"Haematologica"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.celrep.2019.06.039","article-title":"Acute Iron Deprivation Reprograms Human Macrophage Metabolism and Reduces Inflammation In Vivo","volume":"28","author":"Pereira","year":"2019","journal-title":"Cell Rep."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Zhou, J., Tang, Z., Gao, S., Li, C., Feng, Y., and Zhou, X. (2020). Tumor-Associated Macrophages: Recent Insights and Therapies. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00188"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.yexcr.2019.03.005","article-title":"TNF-\u03b1 derived from M2 tumor-associated macrophages promotes epithelial-mesenchymal transition and cancer stemness through the Wnt\/\u03b2-catenin pathway in SMMC-7721 hepatocellular carcinoma cells","volume":"378","author":"Chen","year":"2019","journal-title":"Exp. Cell Res."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Laha, D., Grant, R., Mishra, P., and Nilubol, N. (2021). The Role of Tumor Necrosis Factor in Manipulating the Immunological Response of Tumor Microenvironment. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.656908"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13046-024-02989-x","article-title":"IL6-STAT3-C\/EBP\u03b2-IL6 positive feedback loop in tumor-associated macrophages promotes the EMT and metastasis of lung adenocarcinoma","volume":"43","author":"Hu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12935-022-02527-9","article-title":"Tumor-associated macrophage derived IL-6 enriches cancer stem cell population and promotes breast tumor progression via Stat-3 pathway","volume":"22","author":"Radharani","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.3889\/oamjms.2019.589","article-title":"IL-6 Activities in the Tumour Microenvironment. Part 1","volume":"7","author":"Chonov","year":"2019","journal-title":"Open Access Maced. J. Med. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"155850","DOI":"10.1016\/j.cyto.2022.155850","article-title":"Interleukin-1 (IL-1) and the inflammasome in cancer","volume":"153","author":"Pretre","year":"2022","journal-title":"Cytokine"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0271-5317(89)80071-5","article-title":"Effect of iron deficiency on the stimulation of natural killer cells by macrophage-produced interferon","volume":"9","author":"Hallquist","year":"1989","journal-title":"Nutr. Res."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"DeBarra, C., Ryan, E., Sugrue, M., Ryan, O., Lynn, E., Heneghan, H.M., McCarthy, C., Moynagh, P.N., Sinclair, L.V., and Jones, N. (2024). Iron deficiency in people with obesity drives defective Natural Killer cell mitochondrial fitness and function. bioRxiv.","DOI":"10.1101\/2024.01.10.575005"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Fantini, M., Arlen, P.M., and Tsang, K.Y. (2023). Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1275904"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12967-022-03437-0","article-title":"Natural killer cells: A promising immunotherapy for cancer","volume":"20","author":"Chu","year":"2022","journal-title":"J. Transl. Med."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Castro, F., Cardoso, A.P., Gon\u00e7alves, R.M., Serre, K., and Oliveira, M.J. (2018). Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00847"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Jorgovanovic, D., Song, M., Wang, L., and Zhang, Y. (2020). Roles of IFN-\u03b3 in tumor progression and regression: A review. Biomark. Res., 8.","DOI":"10.1186\/s40364-020-00228-x"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood.2021013472","article-title":"The role of iron in chronic inflammatory diseases: From mechanisms to treatment options in anemia of inflammation","volume":"140","author":"Marques","year":"2022","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Jung, M., Mertens, C., Tomat, E., and Br\u00fcne, B. (2019). Iron as a Central Player and Promising Target in Cancer Progression. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020273"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrfmmm.2014.08.004","article-title":"Oxidative stress preferentially induces a subtype of micronuclei and mediates the genomic instability caused by p53 dysfunction","volume":"770","author":"Xu","year":"2014","journal-title":"Mutat. Res. \/Fundam. Mol. Mech. Mutagen."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Chifman, J., Arat, S., Deng, Z., Lemler, E., Pino, J.C., Harris, L.A., Kochen, M.A., Lopez, C.F., Akman, S.A., and Torti, F.M. (2017). Activated Oncogenic Pathway Modifies Iron Network in Breast Epithelial Cells: A Dynamic Modeling Perspective. PLoS Comput. Biol., 13.","DOI":"10.1371\/journal.pcbi.1005352"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12935-024-03329-x","article-title":"Iron metabolism: Backfire of cancer cell stemness and therapeutic modalities","volume":"24","author":"Yu","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10549-009-0345-x","article-title":"Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen","volume":"119","author":"Habashy","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/1097-0142(19950701)76:1<20::AID-CNCR2820760104>3.0.CO;2-3","article-title":"Transferrin receptor expression in nonsmall cell lung cancer. Histopathologic and clinical correlates","volume":"76","author":"Whitney","year":"1995","journal-title":"Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1158\/0008-5472.CAN-07-2491","article-title":"In vivo switching of human melanoma cells between proliferative and invasive states","volume":"68","author":"Hoek","year":"2008","journal-title":"Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12964-022-00871-x","article-title":"Melanoma cells with diverse invasive potential differentially induce the activation of normal human fibroblasts","volume":"20","author":"Mazurkiewicz","year":"2022","journal-title":"Cell Commun. Signal."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/nyas.13008","article-title":"Iron and cancer: Recent insights","volume":"1368","author":"Manz","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc3495","article-title":"Iron and cancer: More ore to be mined","volume":"13","author":"Torti","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1053\/j.gastro.2003.09.035","article-title":"Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives","volume":"125","author":"Elmberg","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/jhep.2001.22506","article-title":"Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non\u2013iron-related chronic liver disease","volume":"33","author":"Fracanzani","year":"2001","journal-title":"Hepatology"},{"key":"ref_101","first-page":"e45324","article-title":"Comprehensive Review of Red Meat Consumption and the Risk of Cancer","volume":"15","author":"Sivasubramanian","year":"2023","journal-title":"Cureus"},{"key":"ref_102","first-page":"1085","article-title":"Red meat and colorectal cancer","volume":"52","author":"Aykan","year":"2015","journal-title":"Oncol. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"6343","DOI":"10.2147\/OTT.S115438","article-title":"Cancer: Fundamentals behind pH targeting and the double-edged approach","volume":"9","author":"Koltai","year":"2016","journal-title":"OncoTargets Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"103772","DOI":"10.1016\/j.critrevonc.2022.103772","article-title":"Puzzling out iron complications in cancer drug resistance","volume":"178","author":"Abedi","year":"2022","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40880-018-0288-x","article-title":"Amino acid transporter SLC7A11\/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer","volume":"38","author":"Koppula","year":"2018","journal-title":"Cancer Commun."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1089\/ars.2011.4391","article-title":"The Cystine\/Glutamate Antiporter System xc\u2212 in Health and Disease: From Molecular Mechanisms to Novel Therapeutic Opportunities","volume":"18","author":"Lewerenz","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2174\/0929867033457638","article-title":"The Role of Iron Chelation in Cancer Therapy","volume":"10","author":"Buss","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10534-020-00243-3","article-title":"Iron chelators in cancer therapy","volume":"33","author":"Ibrahim","year":"2020","journal-title":"BioMetals"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Grignano, E., Birsen, R., Chapuis, N., and Bouscary, D. (2020). From Iron Chelation to Overload as a Therapeutic Strategy to Induce Ferroptosis in Leukemic Cells. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.586530"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.4049\/jimmunol.1901399","article-title":"Cutting Edge: Activation-Induced Iron Flux Controls CD4 T Cell Proliferation by Promoting Proper IL-2R Signaling and Mitochondrial Function","volume":"204","author":"Yarosz","year":"2020","journal-title":"J. Immunol."},{"key":"ref_111","first-page":"354","article-title":"Effects of iron overload on the immune system","volume":"30","author":"Walker","year":"2000","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.cca.2019.11.029","article-title":"IIron overload: Effects on cellular biochemistry","volume":"504","author":"Sousa","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"ref_113","first-page":"430","article-title":"Analysis of Natural Killer cell functions in patients with hereditary hemochromatosis","volume":"19","author":"Claus","year":"2020","journal-title":"EXCLI J."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1440-1746.1988.tb00212.x","article-title":"The effect of iron, iron-binding proteins and iron-overload on human natural killer cell activity","volume":"3","author":"Chapman","year":"1988","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s00018-016-2194-1","article-title":"Mechanisms of ferroptosis","volume":"73","author":"Cao","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Yang, J., Hu, S., Bian, Y., Yao, J., Wang, D., Liu, X., Guo, Z., Zhang, S., and Peng, L. (2022). Targeting Cell Death: Pyroptosis, Ferroptosis, Apoptosis and Necroptosis in Osteoarthritis. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.789948"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41420-021-00579-w","article-title":"Ferroptosis: A cell death connecting oxidative stress, inflammation and cardiovascular diseases","volume":"7","author":"Yu","year":"2021","journal-title":"Cell Death Discov."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41419-020-2298-2","article-title":"Ferroptosis: Past, present and future","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Tang, L., Liu, S., Li, S., Chen, Y., Xie, B., and Zhou, J. (2023). Induction Mechanism of Ferroptosis, Necroptosis, and Pyroptosis: A Novel Therapeutic Target in Nervous System Diseases. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241210127"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: A Review of Programmed Cell Death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol. Pathol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-4827(02)00027-7","article-title":"Necrosis: A specific form of programmed cell death?","volume":"283","author":"Proskuryakov","year":"2003","journal-title":"Exp. Cell Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41418-018-0252-y","article-title":"Autophagy-dependent cell death","volume":"26","author":"Denton","year":"2019","journal-title":"Cell Death Differ."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Hajibabaie, F., Abedpoor, N., and Mohamadynejad, P. (2023). Types of Cell Death from a Molecular Perspective. Biology, 12.","DOI":"10.3390\/biology12111426"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ccell.2024.03.011","article-title":"The roles of ferroptosis in cancer: Tumor suppression, tumor microenvironment, and therapeutic interventions","volume":"42","author":"Lei","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","article-title":"Targeting ferroptosis as a vulnerability in cancer","volume":"22","author":"Lei","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Xu, J., Lin, X., Han, T., Zhou, Q., Su, Y., Jiang, S., Xiao, X., and Liu, T. (2022). Regulation mechanism of ferroptosis and its research progress in tumor immunotherapy. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.1045548"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/imr.13235","article-title":"Ferroptosis in immunostimulation and immunosuppression","volume":"321","author":"Tang","year":"2024","journal-title":"Immunol. Rev."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s10495-021-01663-3","article-title":"Release mechanisms of major DAMPs","volume":"26","author":"Murao","year":"2021","journal-title":"Apoptosis"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Chen, X., Kang, R., Kroemer, G., and Tang, D. (2021). Ferroptosis in infection, inflammation, and immunity. J. Exp. Med., 218.","DOI":"10.1084\/jem.20210518"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","article-title":"Ferroptosis in cancer therapy: A novel approach to reversing drug resistance","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Wang, P., and Lu, Y.Q. (2022). Ferroptosis: A Critical Moderator in the Life Cycle of Immune Cells. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.877634"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Lin, Z., Zou, S., and Wen, K. (2024). The crosstalk of CD8+ T cells and ferroptosis in cancer. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1255443"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Qu, G., Liu, H., Li, J., Huang, S., Zhao, N., Zeng, L., and Deng, J. (2023). GPX4 is a key ferroptosis biomarker and correlated with immune cell populations and immune checkpoints in childhood sepsis. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-32992-9"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-022-01004-z","article-title":"ACSL4, PUFA, and ferroptosis: New arsenal in anti-tumor immunity","volume":"7","author":"Gan","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.3747\/co.23.2840","article-title":"Hepcidin and ferroportin expression in breast cancer tissue and serum and their relationship with anemia","volume":"23","author":"Pan","year":"2016","journal-title":"Curr. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12964-024-01769-6","article-title":"Inhibition of IRP2-dependent reprogramming of iron metabolism suppresses tumor growth in colorectal cancer","volume":"22","author":"Hwang","year":"2024","journal-title":"Cell Commun Signal."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/brain\/awq042","article-title":"A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha","volume":"133","author":"Seidel","year":"2010","journal-title":"Brain"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1093\/neuonc\/noad136","article-title":"A closer look at the role of iron in glioblastoma","volume":"25","author":"Shenoy","year":"2023","journal-title":"Neuro-Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"111823","DOI":"10.1016\/j.intimp.2024.111823","article-title":"Serum iron element: A novel biomarker for predicting PD-1 immunotherapy efficacy","volume":"131","author":"Luan","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40170-022-00284-x","article-title":"An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells","volume":"10","author":"Fujisawa","year":"2022","journal-title":"Cancer Metab."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/jcph.113","article-title":"Iron chelation in the treatment of cancer: A new role for deferasirox?","volume":"53","author":"Bedford","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/path.5104","article-title":"The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers","volume":"246","author":"Tury","year":"2018","journal-title":"J. Pathol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"7625","DOI":"10.1158\/1078-0432.CCR-10-3099","article-title":"Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies","volume":"17","author":"Ba","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1056\/NEJMc1105726","article-title":"Deferoxamine for advanced hepatocellular carcinoma","volume":"365","author":"Yamasaki","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s13046-019-1397-3","article-title":"Iron and leukemia: New insights for future treatments","volume":"38","author":"Wang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Kuang, F., Liu, J., Tang, D., and Kang, R. (2020). Oxidative Damage and Antioxidant Defense in Ferroptosis. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.586578"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Veglia Tranchese, R., Battista, S., Cerchia, L., and Fedele, M. (2024). Ferroptosis in Cancer: Epigenetic Control and Therapeutic Opportunities. Biomolecules, 14.","DOI":"10.3390\/biom14111443"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"eadg3049","DOI":"10.1126\/scitranslmed.adg3049","article-title":"Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer","volume":"15","author":"Li","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Beretta, G.L., and Zaffaroni, N. (2023). Radiotherapy-induced ferroptosis for cancer treatment. Front. Mol. Biosci., 10.","DOI":"10.3389\/fmolb.2023.1216733"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12645-023-00234-2","article-title":"Enhanced cancer immunotherapy through synergistic ferroptosis and immune checkpoint blockade using cell membrane-coated nanoparticles","volume":"14","author":"Mu","year":"2023","journal-title":"Cancer Nanotechnol."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Deng, J., Zhou, M., Liao, T., Kuang, W., Xia, H., Yin, Z., Tan, Q., Li, Y., Song, S., and Zhou, E. (2022). Targeting Cancer Cell Ferroptosis to Reverse Immune Checkpoint Inhibitor Therapy Resistance. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.818453"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/24\/4156\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:54:06Z","timestamp":1760115246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/24\/4156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":151,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["cancers16244156"],"URL":"https:\/\/doi.org\/10.3390\/cancers16244156","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,13]]}}}